Friday, April 5, 2019

Investor Ideas #Potcasts, #Cannabis News and Stocks on the Move: (CSE: $DIXI_U.C), (CSE: $SNN.C), (TSX: $ACB.TO) (NYSE: $ACB), (TSX: $APHA.TO) (NYSE: $APHA), (CSE: $SOL.C)

Investor Ideas #Potcasts, #Cannabis News and Stocks on the Move:  (CSE: $DIXI_U.C), (CSE: $SNN.C), (TSX: $ACB.TO) (NYSE: $ACB), (TSX: $APHA.TO) (NYSE: $APHA), (CSE: $SOL.C)

Delta, Kelowna, BC –April 5th, 2019 ( Newswire), a global news source covering leading sectors including marijuana and hemp stocks and its potcast site,  release today’s edition of potcastsCM - cannabis news and stocks to watch plus insights from thought leaders and experts.

Listen to the podcast:

Today’s podcast overview/transcript:

Good afternoon and welcome to another “potcast” looking at cannabis news, stocks to watch as well as insights from experts and industry leaders.

Today we are looking at announcements from Dixie Brands Inc, Sunniva Inc, Aurora Cannabis Inc. Aphria Inc. and SOL Global Investments Corp.

Dixie Brands Inc.  (CSE: DIXI.U), (OTC: DXBRF), one of the cannabis industry's leading consumer packaged goods (CPG) companies, has announced plans to introduce a new confectionary product called Dixie Bursts™. The pulled taffy chews will be sold in assorted packages containing Blue Raspberry, Mango and Strawberry flavors. Each individually-wrapped Burst will contain 10 milligrams of THC.

"Dixie has been crafting quality infused-cannabis products for nearly a decade and is constantly seeking new ways to satisfy the evolving needs of our consumers who love to explore new flavors and formats," said Andrew Floor, Dixie's Vice President of Marketing. "We've had a phenomenal reaction to our latest innovation, Dixie Bursts, a hand-pulled taffy which is absolutely bursting with flavor and has a softer texture than the few comparable products in the market today."
Edibles are gaining popularity in jurisdictions where cannabis use is permitted, with sales growth rates outpacing those of dried flower. For example, according to BDS Analytics data for January 2019 in Colorado, one of the most mature cannabis markets in the U.S., sales of both flower and pre-rolled joints declined from one year earlier and now represent less than half of total sales.  Sales of ingestibles in the state increased by 17% over the same period, with the candy sub-category growing by 25%.

Sunniva Inc. (CSE: SNN) (OTCQB: SNNVF), a North American provider of cannabis products and services, announced preliminary revenue of $14.0 million for the three month period ended March 31, 2019.  This represents a 169% increase over the $5.2 million in revenue generated in the comparative three-month period from 2018.

In California, Sunniva began selling cannabis products in the first three months of 2019 through its wholly-owned subsidiary, CP Logistics, LLC with preliminary revenue of $10.0 million (USD $7.5 million). Revenue was comprised of product sales from premium flower, vape cartridges and concentrates. In March, Sunniva unveiled its first three in-house brands, Sun Fire, KYNDNESS and Herbella, and announced that additional super premium brands will be launched in conjunction with production from the 325,000 sq. ft. purpose-built greenhouse under construction in Cathedral City, California.

The Company's other wholly owned subsidiaries, Full-Scale Distributors, LLC and Natural Health Services Ltd., contributed first quarter 2019 revenue of $2.3 million and $1.7 million, respectively.

"In California, we now have the strategic pillars in place to ensure scalability and growth for our newly announced brands and we are very proud of our entire team for the execution and delivery of a very strong first quarter," said Dr. Anthony Holler, CEO of Sunniva. "Our $14.0 million in revenue during the first quarter is close to the total revenue generated by Sunniva in all of 2018. With strong leadership and operating assets producing premium cannabis products, supported by our recent distribution company acquisition, we continue to demonstrate our ability to achieve significant revenue growth and secure shelf space for our Sunniva brands throughout the state."

Aurora Cannabis Inc. (TSX: ACB) (NYSE: ACB), announced today that the Company has been selected by the German Bundesinstitut für Arzneimittel und Medizinprodukte BfArM (Federal Institute for Drugs and Medical Devices) as one of three winners in the public tender to cultivate and distribute medical cannabis in Germany. The contract will be formalized at the earliest on April 17, 2019, pending the outcome of an appeal procedure on which a ruling is anticipated by April 10, 2019.

The tender saw 79 companies participating,  with the winners able to establish production in Germany upon the completion of the contract associated with the tender. The selection process was based on the submission of a concept for domestic cannabis production, delivery and pricing. Aurora's concept, judged on criteria such as facility design, quality, security and logistics, received the highest ranking out of all concepts submitted, validating the Company's leadership in integrated cultivation, production and delivery.
The Company was awarded the maximum number of 5 of the 13 lots in the tender over a period of four years with a minimum supply of 4000kg total. The cannabis produced will be sold to the German government and supplied to wholesalers for distribution to pharmacies.

Aphria Inc. (TSX: APHA) (NYSE: APHA  is also entering the German market having announced that its German subsidiary Aphria Deutschland GmbH has been selected by the German Federal Institute for Drugs and Medical Devices ("BfArM") to receive a license for the domestic cultivation of medical cannabis. The provisional decision announced by BfArM is subject to a mandatory 10-day standstill period for public contracts, which permits unsuccessful bidders to challenge the decision before the final contract is signed. BfArM's decision would grant Aphria 5 of the 13 available lots, each with a minimum annual capacity of 200 kg.

"Aphria is proud to have been selected as a successful applicant in the German tender process, a testament to our high production quality standards," said Hendrik Knopp, Managing Director of Aphria Germany. "The decision from BfArM is a validation of our strategic approach to supporting the German medical cannabis market, including with high-quality, domestic production to secure vital supply for patients. We are very pleased with our continued business momentum in Germany."

SOL Global Investments Corp. (CSE:SOL) (OTCQB:SOLCF),  announced that it intends to spin off its wholly-owned subsidiary, Scythian Biosciences Inc. ("SBI"), into an independent, publicly-traded company. Upon closing of the Spin-off, which is expected to occur on or before September 30, 2019, SOL shareholders will own shares of both companies.

In connection with the Spin-off, SBI will be renamed "Impact Biosciences Corp" ("Impact") and will continue to pursue a drug development in the United States for the treatment of concussions and traumatic brain injury with its proprietary Cannabinoid combination drug candidate, which is being developed under contract with the University of Miami. Impact's mission is to become the first accepted drug regimen for concussive treatment. Impact has a collaboration with the University of Miami and its world-renowned neuroscientific team to conduct pre-clinical and clinical trials of its drug regimen.

Impact's Traumatic Brain Injury (TBI) Combination Therapy is currently in the pre-clinical research phase and is undergoing animal testing. Upon completion of this pre-clinical phase and applicable IND enabling studies, Impact will prepare and file an investigational new drug ("IND") application with the FDA, which, if granted, would permit Impact to begin human testing. Impact has applied for two patents related to its TBI treatment strategy, involving the combination of multiple chemical pathways into a therapeutic regimen targeted at reducing post-injury inflammation and inhibiting the resultant gliosis and the immune cascade. Impact has found a unique way to apply several pre-existing drugs in a way not previously done to target these processes.

Investor ideas reminds all listeners to read our disclaimers and disclosures on the  website and this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment   

Subscribe to the new cannabis podcast series:

To hear more podcasts visit: podcasts are also available on iTunes,  Spotify, Google Play Music, Stitcher, Spreaker,   YouTube via Spreaker,  iHeartradio and Tunein.

Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708

Get the cannabis/hemp stock directory as an Investor ideas member , plus get weekly updates with new pot stocks added and get the daily potcast for Investor Ideas #Potcasts #Cannabis News and Stocks on the Move.  Learn more

About - News that Inspires Big Investing Ideas is a recognized news source publishing third party news and press releases plus we create original financial content. Learn about investing in stocks and  sector trends  from with our news alerts , articles , podcasts and videos  talking about cannabis,  crypto,  technology including  AI and IoT , mining ,sports biotech, water, renewable energy and more . original branded content includes the daily Crypto Corner and Podcast, Play by Play sports and stock news column, Investor Ideas #Potcasts #Cannabis News and Stocks on the Move podcast and column,  Cleantech and Climate Change Podcast and  the AI Eye Podcast and column covering developments in AI. 

Disclaimer/Disclosure: is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers.
Learn more about Investor ideas podcast and news publication  services and costs 
Global investors must adhere to regulations of each country.

Please read privacy policy:

Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.

Follow us on Social Media


No comments:

Post a Comment